Cellectar Biosciences (CLRB)CEO bought ~$25K

~$25K

Approx. value · 8,680 sh @ $2.88

20K

Holds after · shares reported

Traded

May 7, 2026

Filed

May 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 4, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. May 7, 2026 · this disclosureInsider · 10 days before an 8-KCEO purchased ~$25K of CLRB shares in the open market

What came next

1. May 7, 2026Insider · 10 days before an 8-KOfficer purchased ~$25K of CLRB shares in the open market
2. May 14, 2026Company filing · Form 8-K · ResultsReported its results
3. May 17, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.”
4. Jul 7, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As described in Item 5.07 below, on July 7, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Cellectar Biosciences, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s 2021 Stock Incentive Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan by 2,000,000 shares.”
5. Aug 13, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cellectar Biosciences

OQRO holds no insider, Congress, fund or contract record for Cellectar Biosciences dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CLRB page.

Other recent filings by James V Caruso, Chief Executive Officer

• SEC Form 4 at Cellectar Biosciences (CLRB)Jul 3, 2025

The full history of James V Caruso, Chief Executive Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cellectar Biosciences

• SEC Form 4May 12, 2026
• SEC Form 4Dec 16, 2025
• SEC Form 4Jul 3, 2025
• SEC Form 4Jul 3, 2025
• SEC Form 4Jul 3, 2025
• SEC Form 4Mar 13, 2025

Everything OQRO holds on this company is on its CLRB page.